Controlled Studies in Clinical Cancer Research
- 13 July 1972
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 287 (2) , 75-78
- https://doi.org/10.1056/nejm197207132870205
Abstract
A review of abstracts and papers reporting clinical trials of new anticancer agents reveals that only a small percentage have been controlled. Arguments against employing randomized controls in such trials are understandable but hardly valid at the present stage in cancer research. Randomization of drugs tested or dosage regimens at the earliest stages of clinical use is needed to evaluate relative therapeutic efficacy and toxicity. Potent ethical arguments also require that when a new drug is tried, patients should be given a 50–50 chance of receiving the conceivably better standard therapy. An important and subtle consideration, that of how long to continue a controlled trial, requires continued development of the study-design process and new uses of peer review.Keywords
This publication has 10 references indexed in Scilit:
- Revascularization of the heart—numerators in search of denominatorsAmerican Heart Journal, 1971
- Urokinase pulmonary embolism trial. Phase 1 results: a cooperative studyJAMA, 1970
- The Coronary Drug Project. Initial findings leading to modifications of its research protocolJAMA, 1970
- Comparison of daily versus weeklyl-asparaginase for the treatment of childhood acute leukemiaThe Journal of Pediatrics, 1970
- Estrogen treatment for cancer of the prostate.Early results with 3 doses of diethylstilbestrol and placeboCancer, 1970
- Single Agents in Cancer ChemotherapyPublished by Springer Nature ,1970
- A Challenge to Clinical InvestigatorsGastroenterology, 1969
- A Controlled Trial of Urethane Treatment in Multiple MyelomaBlood, 1966
- Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramideJournal of Chronic Diseases, 1960